Almadrones Lois, McGuire Debroah B, Walczak Janet Ruth, Florio Colleen M, Tian Chunqiao
Sloan-Kettering Cancer Center, New York, NY, USA.
Oncol Nurs Forum. 2004 May;31(3):615-23. doi: 10.1188/04.ONF.615-623.
PURPOSE/OBJECTIVES: To evaluate the psychometric properties of two adapted scales, one for functional status and one for peripheral neuropathy secondary to neurotoxic chemotherapy.
Repeated measures methodologic design conducted within a Gynecologic Oncology Group (GOG) phase III clinical trial that randomly assigned patients with advanced epithelial ovarian cancer to cisplatin and cyclophosphamide or cisplatin and paclitaxel.
8 GOG institutions participating in the GOG clinical trial.
88 evaluable outpatients enrolled in the GOG clinical trial. Sample size at time 1 (T1) was 88 patients and at time 2 (T2) was 67 patients.
All scales were administered at T1 (prior to initiation of chemotherapy) and T2 (after six cycles of chemotherapy but prior to second-look laparotomy). Internal consistency reliability, criterion validity, and construct validity were evaluated, and clinical application was explored.
Self-reported peripheral neuropathy and functional status (comprised of physical function and role function subscales), the GOG performance status scale, and the GOG toxicity criteria.
Reliability coefficients at T1 were physical function = 0.83, role function = 0.96, and peripheral neuropathy = 0.91; at T2, they were physical function = 0.83, role function = 0.92, and peripheral neuropathy = 0.89. At T1, physical function and role function correlated positively with performance status. Peripheral neuropathy correlated positively with GOG toxicity criteria used at T2. Principal component factor analysis suggested that the functional status scale had a two-factor structure with factors representing general and specific mobility and that the peripheral neuropathy scale also had a two-factor structure with factors representing foot and hand neuropathy.
The physical function, role function, and peripheral neuropathy scales have internal consistency, reliability, criterion validity, and construct validity. However, revision of the scales should address modification of specific questions and consider increasing the Likert scale from a four-point to a five- or seven-point scale to enhance clinical sensitivity and application.
With minor modifications, these scales should be useful in assessing physical function, role function, and peripheral neuropathy in patients who receive agents that may cause peripheral neuropathy.
目的/目标:评估两个改编量表的心理测量特性,一个用于功能状态,另一个用于神经毒性化疗继发的周围神经病变。
在妇科肿瘤学组(GOG)的一项III期临床试验中采用重复测量方法学设计,该试验将晚期上皮性卵巢癌患者随机分配至顺铂和环磷酰胺组或顺铂和紫杉醇组。
8个参与GOG临床试验的机构。
88名可评估的门诊患者参加了GOG临床试验。第1次测量(T1)时样本量为88例患者,第2次测量(T2)时为67例患者。
所有量表均在T1(化疗开始前)和T2(化疗六个周期后但二次剖腹探查术前)进行施测。评估内部一致性信度、效标效度和结构效度,并探讨临床应用情况。
自我报告的周围神经病变和功能状态(由身体功能和角色功能子量表组成)、GOG体能状态量表以及GOG毒性标准。
T1时的信度系数为身体功能=0.83,角色功能=0.96,周围神经病变=0.91;T2时,身体功能=0.83,角色功能=0.92,周围神经病变=0.89。在T1时,身体功能和角色功能与体能状态呈正相关。周围神经病变与T2时使用的GOG毒性标准呈正相关。主成分因子分析表明,功能状态量表具有双因子结构,因子分别代表一般和特定的活动能力,周围神经病变量表也具有双因子结构,因子分别代表足部和手部神经病变。
身体功能、角色功能和周围神经病变量表具有内部一致性、信度、效标效度和结构效度。然而,量表的修订应针对具体问题进行修改,并考虑将李克特量表从四点量表增加到五点或七点量表,以提高临床敏感性和应用价值。
稍作修改后,这些量表应有助于评估接受可能导致周围神经病变药物治疗的患者的身体功能、角色功能和周围神经病变。